SOCM
SR One Capital Management Portfolio holdings
AUM
$461M
This Quarter Return
+27.43%
1 Year Return
+23.25%
3 Year Return
+188.96%
5 Year Return
–
10 Year Return
–
AUM
$499M
AUM Growth
+$499M
(+56%)
Cap. Flow
+$93.9M
Cap. Flow
% of AUM
18.84%
Top 10 Holdings %
Top 10 Hldgs %
99.49%
Holding
11
New
2
Increased
1
Reduced
–
Closed
–
Top Buys
| 1 |
ZBIO
Zenas BioPharma, Inc. Common Stock
ZBIO
|
$83.1M |
| 2 |
ORKA
Oruka Therapeutics, Inc. Common Stock
ORKA
|
$9.2M |
| 3 |
enGene Holdings
ENGN
|
$1.64M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$3.85B
| $196M | 39.29% |
2,346,630
| – | – |
|
|
ZBIO
2
Zenas BioPharma, Inc. Common Stock
ZBIO
$674M
| $83.1M | 16.66% |
+4,911,539
| New | +$83.1M |
|
3
ARS Pharmaceuticals
SPRY
$1.15B
| $58.2M | 11.67% |
4,012,903
| – | – |
|
4
CRISPR Therapeutics
CRSP
$4.71B
| $49.3M | 9.88% |
1,048,951
| – | – |
|
5
Design Therapeutics
DSGN
$315M
| $35.1M | 7.04% |
6,526,476
| – | – |
|
6
Mineralys Therapeutics
MLYS
$1.03B
| $24.4M | 4.9% |
2,016,822
| – | – |
|
|
ALMS
7
Alumis Inc. Common Stock
ALMS
$479M
| $20.9M | 4.2% |
1,959,896
| – | – |
|
8
Nkarta
NKTX
$151M
| $15.1M | 3.02% |
3,333,333
| – | – |
|
|
ORKA
9
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $9.2M | 1.84% |
+375,330
| New | +$9.2M |
|
|
10
enGene Holdings
ENGN
$236M
| $4.94M | 0.99% |
747,750
+247,750
| +50% | +$1.64M |
|
11
KALA BIO
KALA
$78.8M
| $2.53M | 0.51% |
443,661
| – | – |
|